Bromantane (Ladasten)Бромантан
What the studies found
Comparison in people · 2000
No operator-performance improvement in rested volunteers
- Principal operator performance
- No improvement detected
- Subjective state
- No change detected
- EEG and tremor
- Changes reportedNo numerical EEG/tremor effect size or dose in the indexed abstract
In a placebo comparison involving 10 healthy volunteers, Bromantane changed EEG and tremor measures but did not improve the main operator-performance tests or subjective state.
Study notes · methods, sources and limitations
Participants or model 10 healthy volunteers
Design Ten healthy rested volunteers, single oral Bromantane administration versus placebo; EEG, tremor and operator tests.
Important limitations
- The participants were rested; the experiment did not test performance under fatigue.
- Very small sample and single administration. Randomization and allocation details were not established from the abstract. The proposed relevance to fatigued operators was not demonstrated by this rested-volunteer comparison.
- This experiment tested rested participants. Fatigued-operator benefit was a hypothesis, not an observed result.
Voen Med Zh. 321(8):61–65, 96 · Indexed abstract
Animal research · 2012
Bromantane and splenic T-cell populations after 20 days of social stress in mice
- Splenic CD3+ T cells
- 31.3% vs 27.9%Bromantane vs saline; unstressed 32.0%
- Splenic CD4+CD8− cells
- 19.3% vs 17.1%Bromantane vs saline; unstressed 21.8%
- Thymus mass index
- 14.4 vs 14.8 mg per 10 g body massBromantane vs saline; unstressed 22.2 mg per 10 g
Splenic CD3+ cells were 31.3% with Bromantane versus 27.9% with saline and 32.0% in unstressed controls. Thymus mass remained low in both stressed arms.
Study notes · methods, sources and limitations
Participants or model Male C57BL/6 mice, 10 per stressed arm, plus unstressed controls
Design Male C57BL/6 mice underwent 20 days of social stress. Stressed groups received saline or Bromantane 30 mg/kg intraperitoneally on days 16–20 (10 per arm). An unstressed group served as a reference. Researchers measured organ weight and splenic T-cell percentages by flow cytometry one day after the final dose.
Important limitations
- The T-cell table marks tests against unstressed controls and does not report a direct Bromantane–saline p value. The related 2014 publication describes a 30-day model. Whether these reports shared animals is unresolved.
- Cell proportions moved toward the unstressed values. The authors found no effect on the stress-associated change in lymphoid organ mass.
Russian Journal of Biotherapy. 2012;11(1):39–43. · Publication record
Randomized study in people · 2009
Fatigue-related symptoms improved over 28 days
- Symptom improvement
- Reported over 28 daysNumerical table values were not transcribed in the prior review
- Harms described
- Mild restlessness during treatment; transient dizziness after withdrawalEvent denominators not supplied in the checked narrative
A small randomized comparison of 40 patients reported symptom improvement with Ladasten. Mild restlessness during treatment and transient dizziness after withdrawal were also reported.
Study notes · methods, sources and limitations
Participants or model 40 patients: 20 per diagnosis, randomized within diagnosis to active treatment or placebo (10 per cell)
Design 40 patients: 20 with each of two diagnoses, randomized within diagnosis to active drug or placebo; four cells of ten. Single-blind, 28-day treatment and seven-day post-treatment observation.
Important limitations
- Four small groups; multiple symptom outcomes. Seven-day post-treatment observation cannot establish long-term dependence or safety. Overlap with other 2009 Ladasten reports remains unresolved; do not sum cohorts.
- Existing publisher methods and narrative review used. Table recovery is deferred; possible overlap with other 2009 reports remains unresolved.
Mental Disorders in General Medicine. 2009(1):57–60 · Publication record
About Bromantane
Names in this research collection
Bromantan · Ladasten · Ладастен
A synthetic adamantane-derived compound studied in Russian fatigue and stress research. It belongs to the actoprotector literature and is not a peptide.
Identity / background source ↗
Research background
An adamantane-derived small molecule, also known as Ladasten. The expanded archive connects clinical asthenia studies, operator experiments and preclinical mechanisms, with model-specific limitations and safety findings.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
Russian ME/CFS and fatigue research ↗
Archival sources and remaining questions ↗ · Conference sources and research collaborators ↗
More study findings
Animal research · 1996
Bromantane and cellular immune responses in experimental models
- Delayed skin hypersensitivity and lymph node response
- IncreasedSeparate cellular immune assays
- T-cell precursor maturation
- Increased
- Immune changes in NZB mice
- Partial prevention reported
The authors reported increased delayed skin hypersensitivity and maturation of precursor T cells, with partial prevention of selected immune changes in NZB mice.
Study notes · methods, sources and limitations
Participants or model Animal and laboratory models, including NZB mice
Design In vivo and in vitro cellular immune assays. The abstract does not provide arm sizes or dose.
Important limitations
- The accessible abstract gives no dose, group sizes or effect magnitudes.
Immunologiya. 1996;(4):28–30. · Indexed abstract
Animal research · 1996
Bromantane and antibody-producing cells in mice
- Antibody-producing B cells
- Increased number and functional activityCBA and C57BL/6J mice
- IgM production
- IncreasedInduced immune-deficit mouse models
Bromantane increased the number and activity of antibody-producing B cells in mice. The authors also reported increased IgM production in induced immune-deficit models.
Study notes · methods, sources and limitations
Participants or model CBA and C57BL/6J mice and secondary immunodeficiency models
Design In vivo mouse experiments. The abstract reports injected doses of 10–200 mg/kg in antigen-response experiments and describes separate induced immune-deficit models.
Important limitations
- The abstract gives a dose range but no arm sizes, effect sizes or individual dose results. Overlap with experiments disclosed by the same group in RU1826906C is unresolved.
Immunologiya. 1996;(4):31–34. · Indexed abstract
Animal research · 2014
Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state.
- Thymus and spleen weight
- Shifted toward unstressed valuesStress lowered thymus weight and raised spleen weight.
In the 30-day social-stress model, Ladasten shifted immune organ weights and T-cell populations toward control values. A related 2012 paper used a 20-day model and reported persistent low thymus mass.
Study notes · methods, sources and limitations
Participants or model Animal or animal-tissue experiments
Design Male C57BL/6 mice under 30 days of social stress. Ladasten 30 mg/kg intraperitoneally for five days.
- T-cell populations
- Shifted toward unstressed valuesStress reduced T-cell fractions and shifted the CD4/CD8 ratio.
Important limitations
- Original full text and detailed methods have not been reviewed. Experimental findings do not establish human efficacy, dosing or long-term safety.
- Group sizes and numerical effect estimates are unavailable in the abstract. The related 2012 paper used a different stress duration, and overlap between the reports is unresolved.
Bulletin of experimental biology and medicine; 2014 Jan · Indexed abstract
Observational study · 2010
Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]
- CGI-S responders
- 76.0%
- CGI-I responders
- 90.8%
- First reported antiasthenic effect
- Day 3
Reports symptom and quality-of-life improvements during 28 days of Ladasten treatment and follow-up. The abstract reports adverse events in 3% and discontinuation in 0.8%.
More reported outcomes
- Adverse effects
- 3%
- Stopped therapy
- 0.8%
- Serious adverse effects
- None reported in this cohort
Study notes · methods, sources and limitations
Participants or model 728 analyzable patients with psychoautonomic syndrome in 28 Russian centers
Design Uncontrolled multicenter report: 28 centers, 728 analyzed patients (91.6% of the enrolled sample). Ladasten 50–100 mg/day for 28 days; follow-up one month after treatment.
Important limitations
- No concurrent comparator is described in the abstract; improvement alone does not establish causality. PMID 21322821 has the same title, cohort and abstract: treat it as a related report of this cohort, not independent replication. Short follow-up and incomplete ascertainment cannot rule out uncommon or long-term harms.
- Responder percentages use different CGI scales. There is no concurrent placebo comparison in the abstract; the results are not independent of duplicate reports of this cohort.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 110(5 Suppl 1):17-26. PMID 20559263 · Indexed abstract
- Compound class
- Actoprotector
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Research institutions
- Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Randomized neurasthenia comparison; multicenter and volunteer reports
Study methods
Mixed designs; abstract-level review unless stated otherwise
Independent replication
Related reports may share cohorts; independent confirmation remains unresolved
Source access
Publisher texts, indexed records and explicit document/review scopes below
Safety evidence
Preclinical adverse findings included; human long-term safety and interactions unresolved
Open a topic for the evidence assessment.
More findings, background and history
Chlodantane, Cyclontane and the ADK research program ↗
Bromantane: benefits, research and safety
A guide to the human studies and experimental research behind claims about fatigue, focus and anxiety. Follow each answer to its original research record.
What is Bromantane, and is it a peptide?
Bromantane is an adamantane-derived small molecule, not a peptide. It is also indexed as bromantan and studied under the name Ladasten. Russian research spans actoprotection, fatigue and asthenic disorders.
What benefits have human studies investigated?
Human research includes a placebo-controlled neurasthenia trial and small volunteer studies of mental fatigue and performance. Findings in patients with asthenic symptoms should be distinguished from effects in healthy people seeking better focus or motivation.
Does Bromantane improve focus and performance?
Results depend on the setting. A study in ten rested volunteers found physiological changes but no improvement in principal operator-performance measures. A separate mental-fatigue report described favorable findings. Together, these do not establish a general cognitive enhancement effect.
What does the anxiety research show?
The Ladasten placebo comparison investigated neurasthenia and reported psychostimulant and anxiolytic effects. That population and trial do not establish effectiveness for every anxiety disorder or for self-directed use.
How does Bromantane work?
Experimental research examines effects on dopamine and other neurotransmitter systems. These mechanisms provide hypotheses for clinical research; animal and laboratory findings do not establish a lasting dopamine increase or a predictable change in motivation in people.
What should readers know about safety and social-media claims?
A personal report cannot establish how often a benefit or side effect occurs. The linked clinical and volunteer studies concern particular populations and observation periods; they do not establish long-term safety, safe combinations or equivalence between studied preparations and products advertised online.
Actoprotector research · Adamantane research history · Bemitil research
Additional Bromantane and Ladasten publications
This update adds 33 abstract-based records and seven bibliographic leads. Publications may share participants or experiments; these totals are not counts of independent trials. Human reports, laboratory findings and records awaiting original text are labeled separately.
- 2005: [Effect of ladasten on reproduction function in male rats]. — Animal / experimental
- 2004: [The effect of bromantan on the sexual behavior and conception in rats]. — Animal / experimental
- 2000: [Effect of bromantane on the rat neurologic status in two month course]. — Animal / experimental
- 2014: Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state. — Animal / experimental
- 2000: [Effect of the long term administration of bromantan on the reproductive function in rats]. — Animal / experimental
- 2000: [The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals]. — Animal / experimental
- 1999: [The effect of the actoprotector preparation bromantane on the postnatal development of rat pups]. — Animal / experimental
- 2000: [An acute toxicity study of bromantane]. — Animal / experimental
- 2001: [Complex evaluation of the effect of bromantane on animal behavior]. — Animal / experimental
- 1999: [The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reaction]. — Animal / experimental
- 1999: [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]. — Animal / experimental
- 1997: Bromontan, a new doping agent. — Bibliographic lead
- 2012: [Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types]. — Human comparison
- 2011: Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome. — Animal / experimental
- 2012: [Effect of ladasten on antenatal and postnatal development]. — Animal / experimental
- 2011: [Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients]. — Human comparison
- 2012: Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases. — Animal / experimental
- 2011: [Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice]. — Animal / experimental
- 1995: [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. — Animal / experimental
- 2010: [Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015]. — Animal / experimental
- 2010: Proteomic analysis and identification of ladasten target proteins in rat brain. — Animal / experimental
- 2010: [Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb]. — Animal / experimental
- 2011: [Ladasten in the management of non-motor symptoms of Parkinson's disease]. — Bibliographic lead
- 2010: [Prospects for using ladasten preparations in patients with irritable bowel syndrome]. — Uncontrolled human report
- 2008: [Characteristics of ladasten effect in neurasthenia patients with various EEG parameters]. — Uncontrolled human report
- 2009: Changes in CREB (SER133) content and DNA-binding activity of transcriptional factors in rat brain cells against the background of ladasten exposure. — Animal / experimental
- 2007: The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. — Animal / experimental
- 2006: [Pilot clinical trial of ladasten]. — Uncontrolled human report
- 2006: [Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten]. — Animal / experimental
- 2006: [Thermoprotector properties of a combination of sydnocarb with ladasten]. — Animal / experimental
- 2006: [Comparative study of the effect of Ladasten, Sydnocarb and their combination on physical work ability of laboratory animals]. — Animal / experimental
- 2004: [The effect of ladasten on the activation-induced expression of Fas receptor on T-lymphocytes and their sensitivity to Fas-induced apoptosis]. — Cell experiment
- 2005: [Studying the mechanisms of ladasten action]. — Animal / experimental
- 2005: Psychotropic effects of sidnocarb and ladasten in inbred mice with different reaction to emotional stress. — Animal / experimental
- 2002: Toxic effect of single treatment with bromantane on neurological status of experimental animals. — Animal / experimental
- 2005: The effect of ladasten on gene expression in the rat brain. — Bibliographic lead
- 1998: [Comparative analysis of effects of adapromine, midantan, and bromantane on the bioelectric activity of the rat brain]. — Bibliographic lead
- 1999: [Analysis of pharmacological properties of bromantane]. — Bibliographic lead
- 1995: [Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane]. — Bibliographic lead
- 1995: [The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study]. — Bibliographic lead
Curated by @pepmariner · Evidence standards. Educational information, not medical advice.
What remains unclear
A 30-participant open-label randomized comparison with escitalopram reported a nonsignificant difference in response. The effect estimate leaves equivalence uncertain. The 2006 pilot tables and overlap among later EEG reports remain unresolved. The 2025 combination study was conducted in animals.
Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.
Browse original study records ↗Clinical methods and attrition recovered
The Neznamov paper describes 15 patients per arm, with only seven placebo participants completing. A separate 40-patient report is now linked. These reports require cohort-overlap checks.
What remains unresolved
Recover mental-fatigue, heat/gas and altitude originals; reconcile the 2009 clinical reports before pooling.
Bromantane and Ladasten research
Bromantane is an adamantane-derived small molecule. Ladasten names the same active molecule in the later antiasthenic research program. The 2001 new-use patent explicitly links it to earlier psychostimulant and immunostimulant patents; it does not describe a newly invented molecule.
Identity and patent lineage ↗Patient trials
The 2009 randomized, blinded neurasthenia comparison is distinct from the 2010 multicenter report. The latter analyzes 728 patients and has no concurrent comparator described in its abstract. A second indexed report repeats the same cohort and is not counted as independent replication.
Placebo comparison ↓Performance depends on the setting
The 2000 study in ten rested volunteers did not change principal operator-performance measures. A 2009 mental-fatigue report describes favorable changes, but its full allocation and sample details are still needed. Neither proves safety during sleep loss or hazardous work.
Rested-volunteer record ↓Mechanisms remain model-specific
Rat dopamine-synthesis, kinase, gene-expression and histone studies connect to Vakhitova’s Ladasten program. Human T-cell cultures add a separate immunology branch. These are not demonstrations of lasting brain or immune enhancement in people.
Dissertation abstract and PDF ↗Mixed results and safety findings
The 1995 heat paper has model-dependent findings and ambiguous translated wording. Chronic blood-toxicity and reproductive-development experiments are included alongside favorable animal results. “Actoprotector” is a historical classification, not a guarantee of heat protection or long-term safety.
The certificate’s precise early priority date, Medvedkova’s pharmacokinetics, Sergeeva’s dissertation, operator-learning work and specific accounts of military deployment still lack original documentation.
Patents and claimed inventions
These 5 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
2025 · WO2025040956A2 · Bromantane: maladaptive learning and stimulant-use hypothesesUse · Participants reporting cocaine or amphetamine dependence reportedly stopped on the first intervention day and maintained abstinence for approximately 3 weeks
Reported findings
The patent describes short-term self-reported reductions in stimulant use and cravings, not a controlled addiction-treatment result.
- Stimulant-use observations
- Participants reporting cocaine or amphetamine dependence reportedly stopped on the first intervention day and maintained abstinence for approximately 3 weeksFour-week observationSelf-report; no biochemical confirmation or control group established
- Opioid-use observation
- One opioid-dependent participant reported reduced use and cravingsQualitative individual observation; no numerical reduction given
Use. This 2025 publication proposes bromantane in methods addressing maladaptive learning and stimulant-use disorders.
The indexed WO status is member-specific; this filing is not a completed clinical addiction trial and does not establish the status of every national family member.
- Publication
- WO2025040956A2 ↗ · 2025-02-27
- Earliest priority / filing
- 2023-08-09 / 2024-08-10
- Original applicant / assignee
- Individual
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 94731432 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Drug to treat stimulant addiction
Inventors: Davin RAUTIOLA.
WO2025040956A2 · US20260191802A1 · EP4734971A2 · KR20260049775A · CN121729226A · AU2024326725A1
2020 · WO2020191503A1 · Bromantane and derivatives: fibrosis researchUse · Significant reductions versus vehicle reported
Narrative findings; numerical extraction incomplete
The renal experiment reports lower fibrosis and blood urea nitrogen with bromantane, alongside some neutral or numerical-only organ-weight comparisons.
- Kidney fibrosis and BUN
- Significant reductions versus vehicle reportedExact effect sizes and figure values were not transcribed; no patient trial
- Kidney weight
- Affected-kidney weight showed a numerical reduction; the uninjured-kidney change was described as significantNumerical change is distinguished from statistical significance
Use. The application proposes bromantane-related compounds for lung fibrosis and other organ-disease uses.
Patent experiments and proposed indications are distinct from demonstrated human treatment effects.
- Publication
- WO2020191503A1 ↗ · 2020-10-01
- Earliest priority / filing
- 2019-03-27 / 2020-03-27
- Original applicant / assignee
- Algernon Pharmaceuticals Inc
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 72609163 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
Inventors: Mark Williams.
2009 · RU2376986C2 · Ladasten: pharmaceutical compositionFormulation · 6–7 minutes
Reported findings
The disclosure reports acceptable tablet disintegration and mechanical properties.
- Example tablet disintegration
- 6–7 minutesA reported manufacturing-example result, not onset of clinical action
- Direct-compression tablet properties
- Compressive strength 47.81 ± 1.5 N; abrasion resistance 99.7 ± 0.6%Physical formulation measurements; table also specifies disintegration ≤15 minutes
Formulation. The claims concern a formulated Ladasten preparation, including the active ingredient and excipients.
A formulation claim is narrower than ownership of every use of bromantane and does not establish comparative clinical benefit.
- Publication
- RU2376986C2 ↗ · 2009-12-27
- Earliest priority / filing
- 2006-11-30 / 2006-11-30
- Original applicant / assignee
- Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41643188 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition based on ladasten
Inventors: Сергей Борисович Середенин (RU); Сергей Борисович Середенин; Борис Михайлович Пятин (RU); Борис Михайлович Пятин; Нина Ивановна Авдюнина (RU); Нина Ивановна Авдюнина; Константин Викторович Алексеев (RU); Константин Викторович Алексеев; Любовь Николаевна Грушевская (RU); Любовь Николаевна Грушевская; Александр Сергеевич Сульдин (RU); Александр Сергеевич Сульдин.
2001 · RU2175229C2 · Anxiolytic use of the known Bromantane molecule — RU2175229C2Use · Reduced fear-like response in the high-fear strain and increased activity in the more exploratory strain
Narrative findings; numerical extraction incomplete
The patent reports less fear-related behavior with greater exploration, alongside behavioral activation.
- Maze/exploration result
- Reduced fear-like response in the high-fear strain and increased activity in the more exploratory strainNo transcribed group means or human anxiety outcome
- Diazepam comparison
- The disclosure describes a different activation/sedation profileThis is a laboratory behavioral distinction, not a clinical noninferiority or safety finding
Use. Ladasten anxiolytic-use disclosure; the patent provides a development source rather than independent clinical replication.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2175229C2 ↗ · 2001-10-27
- Earliest priority / filing
- 1999-12-22 / 1999-12-22
- Original applicant / assignee
- Научно-исследовательский институт фармакологии РАМН
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20228716 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Anxiolytic agent
Inventors: С.Б. Середенин; М.А. Яркова; Б.А. Бадыштов; тин Б.М. П; Б.М. Пятин; Н.И. Авдюнина; И.С. Морозов; Т.А. Воронина; Г.Г. Незнамов.
1993 · RU1826906C · Bromantane use as an immunostimulantUse · Increased at 3 hours
Reported findings
The inventors reported an increase in large circulating immune complexes three hours after Bromantane in healthy volunteers. The reported significance concerns a change from baseline.
- Large circulating immune complexes
- Increased at 3 hoursBromantane arm versus its baseline. Placebo arm showed no significant change from baseline.
- Small circulating immune complexes
- Nonsignificant decreaseBromantane arm versus its baseline.
Use. The filing claims Bromantane for immunostimulant use and describes animal immune assays and a healthy-volunteer blood-marker experiment.
The volunteer experiment measured a circulating marker over three hours. The filing does not demonstrate infection prevention or efficacy in an immune disorder.
- Publication
- RU1826906C ↗ · 1993-07-07
- Earliest priority / filing
- 1991-06-21 / 1991-06-21
- Original applicant / assignee
- Research Institute of Pharmacology
- Indexed status
- Not shown; official status unverified · checked 2026-11-10
- Patent family
- 21580448 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Иммуностимулирующее средство «Бромантан»
Inventors: I. S. Morozov; N. G. Artsimovich; T. A. Fadeeva; N. V. Klimova; T. S. Galushina; M. A. Matvienko; B. M. Pyatin; N. M. Zaitseva; S. B. Seredenin; B. I. Lyubimov; N. I. Avdyunina; N. A. Kislyak; O. A. Mikhailova; I. A. Ivanova; O. I. Aksenova; S. A. Sergeeva; V. G. Barchukov; Yu. N. Belyi; V. I. Ratnikov; L. M. Krasnykh.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Linked sources
Explore the research map and unresolved leads ↗
2012 · Bromantane and splenic T-cell populations after 20 days of social stress in miceSplenic CD3+ T cells: 31.3% vs 27.9%
Bromantane and splenic T-cell populations after 20 days of social stress in mice
A. V. Tallerova, L. P. Kovalenko, A. D. Durnev, S. B. Seredenin · Russian Journal of Biotherapy. 2012;11(1):39–43.
Splenic CD3+ cells were 31.3% with Bromantane versus 27.9% with saline and 32.0% in unstressed controls. Thymus mass remained low in both stressed arms.
Results and tables
Reported findings and study design
Reported findings
Male C57BL/6 mice underwent 20 days of social stress. Stressed groups received saline or Bromantane 30 mg/kg intraperitoneally on days 16–20 (10 per arm). An unstressed group served as a reference. Researchers measured organ weight and splenic T-cell percentages by flow cytometry one day after the final dose.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Splenic CD3+ T cells | 31.3% vs 27.9% | Bromantane vs saline; unstressed 32.0% |
| Splenic CD4+CD8− cells | 19.3% vs 17.1% | Bromantane vs saline; unstressed 21.8% |
| Thymus mass index | 14.4 vs 14.8 mg per 10 g body mass | Bromantane vs saline; unstressed 22.2 mg per 10 g |
Splenic T-cell subsets (Table 5)
| Percent of cells | Unstressed | Stress + saline | Stress + Bromantane |
|---|---|---|---|
| CD3+ | 32.0 ± 0.8 | 27.9 ± 1.3 | 31.3 ± 1.0 |
| CD4+CD8− | 21.8 ± 1.0 | 17.1 ± 1.1 | 19.3 ± 0.9 |
| CD4−CD8+ | 10.7 ± 0.7 | 9.4 ± 0.5 | 11.0 ± 0.5 |
The authors report p<0.05 for saline versus unstressed controls on CD3+ and CD4+CD8−. The table gives no direct drug-versus-saline p values.
Cell proportions moved toward the unstressed values. The authors found no effect on the stress-associated change in lymphoid organ mass.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Male C57BL/6 mice, 10 per stressed arm, plus unstressed controls
- Source reviewed
- Original journal issue, Methods and Tables 2–5 checked.
Study limitations
- The T-cell table marks tests against unstressed controls and does not report a direct Bromantane–saline p value.
- The related 2014 publication describes a 30-day model. Whether these reports shared animals is unresolved.
Reviewed 2026-11-10.
1996 · Bromantane and cellular immune responses in experimental modelsDelayed skin hypersensitivity and lymph node response: Increased
Bromantane and cellular immune responses in experimental models
T. S. Galushina, T. A. Fadeeva, N. G. Artsimovich · Immunologiya. 1996;(4):28–30.
The authors reported increased delayed skin hypersensitivity and maturation of precursor T cells, with partial prevention of selected immune changes in NZB mice.
Results and tables
Reported findings and study design
Narrative findings; numerical extraction incomplete
In vivo and in vitro cellular immune assays. The abstract does not provide arm sizes or dose.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Delayed skin hypersensitivity and lymph node response | Increased | Separate cellular immune assays |
| T-cell precursor maturation | Increased | |
| Immune changes in NZB mice | Partial prevention reported |
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- Animal and laboratory models, including NZB mice
- Source reviewed
- Original article abstract available. Full methods and numerical tables require the complete article.
Study limitations
- The accessible abstract gives no dose, group sizes or effect magnitudes.
Reviewed 2026-11-10.
1996 · Bromantane and antibody-producing cells in miceAntibody-producing B cells: Increased number and functional activity
Bromantane and antibody-producing cells in mice
T. S. Galushina, T. A. Fadeeva, N. G. Artsimovich · Immunologiya. 1996;(4):31–34.
Bromantane increased the number and activity of antibody-producing B cells in mice. The authors also reported increased IgM production in induced immune-deficit models.
Results and tables
Reported findings and study design
Narrative findings; numerical extraction incomplete
In vivo mouse experiments. The abstract reports injected doses of 10–200 mg/kg in antigen-response experiments and describes separate induced immune-deficit models.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Antibody-producing B cells | Increased number and functional activity | CBA and C57BL/6J mice |
| IgM production | Increased | Induced immune-deficit mouse models |
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- CBA and C57BL/6J mice and secondary immunodeficiency models
- Source reviewed
- Original article abstract available. Full methods and numerical tables require the complete article.
Study limitations
- The abstract gives a dose range but no arm sizes, effect sizes or individual dose results.
- Overlap with experiments disclosed by the same group in RU1826906C is unresolved.
Reviewed 2026-11-10.
2025 · Bromantane: maladaptive learning and stimulant-use hypotheses — WO2025040956A2Stimulant-use observations: Participants reporting cocaine or amphetamine dependence reportedly stopped on the first intervention day and maintained abstinence for approximately 3 weeks
Bromantane: maladaptive learning and stimulant-use hypotheses — WO2025040956A2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Davin RAUTIOLA · WO2025040956A2 · patent family 94731432
The patent describes short-term self-reported reductions in stimulant use and cravings, not a controlled addiction-treatment result.
Results and tables
Reported patent results
Reported findings
The patent describes short-term self-reported reductions in stimulant use and cravings, not a controlled addiction-treatment result.
Exploratory, uncontrolled, self-reported human observations over four weeks; total enrollment is not established from the narrative.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Stimulant-use observations | Participants reporting cocaine or amphetamine dependence reportedly stopped on the first intervention day and maintained abstinence for approximately 3 weeks | Self-report; no biochemical confirmation or control group established · Four-week observation |
| Opioid-use observation | One opioid-dependent participant reported reduced use and cravings | Qualitative individual observation; no numerical reduction given |
| Comorbid symptoms | Reported improvement in irritability, rumination-related insomnia and other symptoms | Self-rated 5-point scales; figure-level individual values not transcribed |
Participant selection, missing group denominators, no control and self-report prevent efficacy claims. Proposed effects on extinction learning were not directly established by these observations.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Exploratory, uncontrolled, self-reported human observations over four weeks; total enrollment is not established from the narrative.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The indexed WO status is member-specific; this filing is not a completed clinical addiction trial and does not establish the status of every national family member.
- Participant selection, missing group denominators, no control and self-report prevent efficacy claims. Proposed effects on extinction learning were not directly established by these observations.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
2020 · Bromantane and derivatives: fibrosis research — WO2020191503A1Kidney fibrosis and BUN: Significant reductions versus vehicle reported
Bromantane and derivatives: fibrosis research — WO2020191503A1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Mark Williams · WO2020191503A1 · patent family 72609163
The renal experiment reports lower fibrosis and blood urea nitrogen with bromantane, alongside some neutral or numerical-only organ-weight comparisons.
Results and tables
Reported patent results
Narrative findings; numerical extraction incomplete
The renal experiment reports lower fibrosis and blood urea nitrogen with bromantane, alongside some neutral or numerical-only organ-weight comparisons.
Preclinical fibrosis/metabolic-organ experiments; the selected renal comparison uses bromantane, vehicle and telmisartan.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Kidney fibrosis and BUN | Significant reductions versus vehicle reported | Exact effect sizes and figure values were not transcribed; no patient trial |
| Kidney weight | Affected-kidney weight showed a numerical reduction; the uninjured-kidney change was described as significant | Numerical change is distinguished from statistical significance |
| Telmisartan comparator | No significant reduction in the selected BUN or fibrosis measurements | A model-specific result, not proof of clinical superiority |
Multiple diseases and analogues are proposed, but results must remain linked to the compound/model actually tested. Animal organ measures do not establish human antifibrotic efficacy.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Preclinical fibrosis/metabolic-organ experiments; the selected renal comparison uses bromantane, vehicle and telmisartan.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Patent experiments and proposed indications are distinct from demonstrated human treatment effects.
- Multiple diseases and analogues are proposed, but results must remain linked to the compound/model actually tested. Animal organ measures do not establish human antifibrotic efficacy.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
2009 · Ladasten: pharmaceutical composition — RU2376986C2Example tablet disintegration: 6–7 minutes
Ladasten: pharmaceutical composition — RU2376986C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Борис Михайлович Пятин (RU), Борис Михайлович Пятин, Нина Ивановна Авдюнина (RU), Нина Ивановна Авдюнина, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевская (RU), Любовь Николаевна Грушевская, Александр Сергеевич Сульдин (RU), Александр Сергеевич Сульдин · RU2376986C2 · patent family 41643188
The disclosure reports acceptable tablet disintegration and mechanical properties.
Results and tables
Reported patent results
Reported findings
The disclosure reports acceptable tablet disintegration and mechanical properties.
Ladasten tablet manufacturing examples and physical-quality testing.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Example tablet disintegration | 6–7 minutes | A reported manufacturing-example result, not onset of clinical action |
| Direct-compression tablet properties | Compressive strength 47.81 ± 1.5 N; abrasion resistance 99.7 ± 0.6% | Physical formulation measurements; table also specifies disintegration ≤15 minutes |
Tablet properties do not establish bioequivalence, clinical anxiolytic benefit or faster symptom relief. Acceptance limits and measured example values are distinct.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Ladasten tablet manufacturing examples and physical-quality testing.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- A formulation claim is narrower than ownership of every use of bromantane and does not establish comparative clinical benefit.
- Tablet properties do not establish bioequivalence, clinical anxiolytic benefit or faster symptom relief. Acceptance limits and measured example values are distinct.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
1993 · Bromantane use as an immunostimulant — RU1826906CLarge circulating immune complexes: Increased at 3 hours
Bromantane use as an immunostimulant — RU1826906C
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
I. S. Morozov, N. G. Artsimovich, T. A. Fadeeva, N. V. Klimova, T. S. Galushina, M. A. Matvienko, B. M. Pyatin, N. M. Zaitseva, S. B. Seredenin, B. I. Lyubimov, N. I. Avdyunina, N. A. Kislyak, O. A. Mikhailova, I. A. Ivanova, O. I. Aksenova, S. A. Sergeeva, V. G. Barchukov, Yu. N. Belyi, V. I. Ratnikov, L. M. Krasnykh · RU1826906C · patent family 21580448
The inventors reported an increase in large circulating immune complexes three hours after Bromantane in healthy volunteers. The reported significance concerns a change from baseline.
Results and tables
Reported patent results
Reported findings
The inventors reported an increase in large circulating immune complexes three hours after Bromantane in healthy volunteers. The reported significance concerns a change from baseline.
The patent calls the volunteer experiment double-blind. It gives an overall figure of 37 healthy volunteers but identifies 12 given a single 200 mg oral Bromantane dose and 11 given placebo for this comparison. Blood was sampled at baseline and three hours.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Large circulating immune complexes | Increased at 3 hours | Bromantane arm versus its baseline. Placebo arm showed no significant change from baseline. |
| Small circulating immune complexes | Nonsignificant decrease | Bromantane arm versus its baseline. |
| B-cell functional activity in immunodeficient mice | 75–85% vs 30–35% | Patent’s summary of reported recovery with Bromantane and Kemantane, respectively. A common denominator for those percentages is unclear. |
The specified volunteer arms account for 23 of the 37 people mentioned. The filing does not give a direct between-arm statistical test. The 1996 mouse papers may share experiments with the filing.
Source for these results ↗ · Reviewed 2026-11-10
- Population / setting
- The patent calls the volunteer experiment double-blind. It gives an overall figure of 37 healthy volunteers but identifies 12 given a single 200 mg oral Bromantane dose and 11 given placebo for this comparison. Blood was sampled at baseline and three hours.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The volunteer experiment measured a circulating marker over three hours. The filing does not demonstrate infection prevention or efficacy in an immune disorder.
- The specified volunteer arms account for 23 of the 37 people mentioned. The filing does not give a direct between-arm statistical test. The 1996 mouse papers may share experiments with the filing.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-10.
2010 · The antidepressant properties of Ladasten: a pilot studyCGI-I response at eight weeks: 66.7% Ladasten versus 80% escitalopram; p>0.05
The antidepressant properties of Ladasten: a pilot study
· Original journal publication
E. B. Dubnitskaya, D. F. Pushkarev · Mental Disorders in General Medicine. 2010;(3):34–38
CGI-I response was reported in 66.7% versus 80%; the between-group difference was not significant. All 30 completed treatment.
Results and tables
Reported findings and study design
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CGI-I response at eight weeks | 66.7% Ladasten versus 80% escitalopram; p>0.05 | |
| Treatment completion | All 30 participants completed eight weeks |
Open-label groups of 15. This does not establish equivalence, noninferiority or superiority; permitted co-treatment and incomplete adverse-event denominators remain relevant.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- 30 patients with asthenic depression; 15 Ladasten and 15 escitalopram; eight weeks
- Source reviewed
- Original publisher text checked for allocation, completion, CGI-I response and its nonsignificant comparison.
Study limitations
- Open-label, small active-comparator trial; random-number-table allocation is reported, but concealment is not established.
- A nonsignificant difference does not establish equivalence or noninferiority.
- Adjunctive hypnotics were permitted. The reported tolerability advantage needs complete event denominators and independent replication.
Reviewed 2026-11-05.
2006 · Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane
Experimental pharmacokinetics of actoprotective agents: Bromantane and Chlodantane
Experimental Chlodantane; source-specific preparation · Dissertation abstract; third-party transcription
Format: Dissertation abstract transcription · Reviewed: Author-abstract transcription: introduction, conclusions and bibliography checked; full dissertation not recovered
A. V. Safronenko · Candidate of Medical Sciences dissertation. Volgograd, 2006; 124 pages according to catalogue metadata
The dissertation describes two tissue-exchange groups for Chlodantane: brain, liver, testes, kidneys, lungs and skeletal muscle equilibrated relatively rapidly with plasma, while adipose tissue equilibrated slowly. Bromantane was described using three groups.
- Population / setting
- Experimental animal tissue-distribution study; human participants not reported.
- Source reviewed
- Author-abstract transcription: introduction, conclusions and bibliography checked; full dissertation not recovered
Study limitations
- The accessible material is an introduction, conclusions and bibliography transcribed by a third party, not the complete dissertation. Concentration-time tables, half-lives and tissue-specific exposure estimates were not recovered. Occupational-use statements in the introduction concern actoprotectors collectively and do not document a Chlodantane-treated human cohort.
Reviewed 2026-11-01.
2023 · Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors
Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors
Cage-amide family; lead 18a distinct from Chlodantane; Bromantane also tested · Journal publication
E. S. Mozhaitsev, E. V. Suslov, D. A. Rastrepaeva, O. I. Yarovaya, S. S. Borisevich, E. M. Khamitov, D. S. Kolybalov, S. G. Arkhipov, N. I. Bormotov, L. N. Shishkina, O. A. Serova, R. V. Brunilin, A. A. Vernigora, M. B. Nawrozkij, A. P. Agafonov, R. A. Maksyutov, K. P. Volcho, N. F. Salakhutdinov · Viruses. 2023;15(1):29. PMID 36680072; PMCID PMC9865139
The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.
- Population / setting
- Cultured-cell antiviral and cytotoxicity comparisons of cage-amide compounds, with computational target modelling; no human participants.
- Source reviewed
- Original full-text XML reviewed via Europe PMC, including findings, tables and interpretation; procedural chemistry and virology are not reproduced here
Study limitations
- Cell-culture activity does not establish treatment benefit in people. Selectivity index compares cytotoxicity and antiviral concentrations in the assay; it is not a human therapeutic index. The strongest family result must not be transferred to Chlodantane. The paper does not substantiate the Sirius news release’s claim of historical human testing.
Reviewed 2026-11-01.
2025 · Ladasten plus fabomotizole in a paraquat-induced parkinsonian mouse model
Ladasten plus fabomotizole in a paraquat-induced parkinsonian mouse model
V. E. Marievsky, I. A. Lyubansky, S. V. Shangin, L. F. Zaynullina, V. L. Dorofeev · Pharmacokinetics and Pharmacodynamics. 2025;(1):43–52.
The combination improved motor-test performance relative to the paraquat-exposed control group, with the largest reported differences in the third week.
- Population / setting
- C57BL/6 mice; four groups including controls, combination treatment and levodopa
- Source reviewed
- Primary journal abstract reproduced by the Russian Central Scientific Medical Library checked.
Study limitations
- Animal toxin model, not a Parkinson disease treatment trial in people.
- The abstract does not report separate Ladasten-only and fabomotizole-only arms; it cannot establish synergy or each component’s contribution.
- Combination dose and full methods require the original paper; paraquat induction dose is not the treatment dose.
Reviewed 2026-10-08.
2005 · [Effect of ladasten on reproduction function in male rats].
[Effect of ladasten on reproduction function in male rats].
Khamidova TV, Chigirinskiĭ IuL, Morozov IS · Eksperimental'naia i klinicheskaia farmakologiia; 2005 May-Jun
In stressed male rats, Ladasten was associated with improved orienting behavior, sperm measures and fertilizing capacity, and reduced embryo loss.
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Reproductive reports use different exposure schedules and endpoints; possible overlap and formulation details require comparison with the original papers.
Reviewed 2026-10-07.
2004 · [The effect of bromantan on the sexual behavior and conception in rats].Sexual behavior: Duration- and dose-dependent changes
[The effect of bromantan on the sexual behavior and conception in rats].
Kuzubova EA, Bugaeva LI, Spasov AA · Eksperimental'naia i klinicheskaia farmakologiia; 2004 May-Jun
Bromantan altered sexual approach and mating behavior in rats, with effects depending on exposure duration and dose.
Results and tables
Reported findings and study design
Rats received oral Bromantane 30 or 300 mg/kg: three-day course or longer exposure (males two months, females two weeks).
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sexual behavior | Duration- and dose-dependent changes | Numerical behavior scores absent |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Reproductive reports use different exposure schedules and endpoints; possible overlap and formulation details require comparison with the original papers.
Reviewed 2026-10-07.
2000 · [Effect of bromantane on the rat neurologic status in two month course].Sex-dependent motor activity: Lower in males; unchanged or higher in females
[Effect of bromantane on the rat neurologic status in two month course].
Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS · Eksperimental'naia i klinicheskaia farmakologiia; 2000 Sep-Oct
Two-month rat exposure produced dose- and sex-dependent changes in movement, exploration, temperature and body weight. The authors reported no clear dependence-related behavior during follow-up; this is not evidence of absent human dependence risk.
Results and tables
Reported findings and study design
Two-month oral rat exposure at 30, 150 or 600 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sex-dependent motor activity | Lower in males; unchanged or higher in females | |
| Temperature response | Early hypothermia, slight hyperthermia in month 2 | |
| Body-weight response | Increased in females, decreased in males | |
| Recovery period | Physiological/behavioral measures restored within two months after stopping |
No human dependence or long-term safety conclusion follows from the absence of rat dependence signs.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2014 · Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state.Thymus and spleen weight: Shifted toward unstressed values
Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state.
Tallerova AV, Kovalenko LP, Kuznetsova OS, Durnev AD, Seredenin SB · Bulletin of experimental biology and medicine; 2014 Jan
In the 30-day social-stress model, Ladasten shifted immune organ weights and T-cell populations toward control values. A related 2012 paper used a 20-day model and reported persistent low thymus mass.
Results and tables
Reported findings and study design
Narrative findings; numerical extraction incomplete
Male C57BL/6 mice under 30 days of social stress. Ladasten 30 mg/kg intraperitoneally for five days.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymus and spleen weight | Shifted toward unstressed values | Stress lowered thymus weight and raised spleen weight. |
| T-cell populations | Shifted toward unstressed values | Stress reduced T-cell fractions and shifted the CD4/CD8 ratio. |
Group sizes and numerical effect estimates are unavailable in the abstract. The related 2012 paper used a different stress duration, and overlap between the reports is unresolved.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2000 · [Effect of the long term administration of bromantan on the reproductive function in rats].Sperm count at 30 mg/kg: Nonsignificant decrease reported
[Effect of the long term administration of bromantan on the reproductive function in rats].
Khamidova TV, Bugaeva LI, Morozov IS, Spasov AA · Eksperimental'naia i klinicheskaia farmakologiia; 2000 May-Jun
The rat reproduction study reported no effect on fertilizing capacity or embryonal measures under its conditions, alongside changes in reproductive-organ measures. The abstract describes the sperm-count decrease as statistically uncertain.
Results and tables
Reported findings and study design
Oral rat reproduction study: Bromantane 30 or 200 mg/kg/day; males two months, females two weeks.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sperm count at 30 mg/kg | Nonsignificant decrease reported | |
| Fertilization and embryo characteristics | No detected effects in the reported experiment |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Reproductive reports use different exposure schedules and endpoints; possible overlap and formulation details require comparison with the original papers.
Reviewed 2026-10-07.
2000 · [The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals].
[The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals].
Morozov IS, Efimova LP, Kryzhanovskiĭ SA · Eksperimental'naia i klinicheskaia farmakologiia; 2000 Jan-Feb
Animal experiments found changes in cardiac output, heart rate, vascular resistance and catecholamine responses. These physiological effects do not establish cardiovascular benefit in people.
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
1999 · [The effect of the actoprotector preparation bromantane on the postnatal development of rat pups].Litter change after paternal exposure: +0.3%, +14.9%, +23.4% by ascending dose
[The effect of the actoprotector preparation bromantane on the postnatal development of rat pups].
Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS · Eksperimental'naia i klinicheskaia farmakologiia; 1999 Nov-Dec
Parental exposure was followed by changes in offspring growth and behavior that differed between maternal and paternal exposure. The report includes both significant and nonsignificant findings.
Results and tables
Reported findings and study design
Rat parental exposure: oral Bromantane 30, 150 or 600 mg/kg/day; females 15 days, males 60 days. Offspring of treated males and treated females assessed separately.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Litter change after paternal exposure | +0.3%, +14.9%, +23.4% by ascending dose | Not statistically significant |
| Litter change after maternal exposure | −34.9%, +45%, −44.2% by ascending dose | Middle dose p<0.05; other changes nonsignificant |
| Paternal-series offspring movement at day 40 | 8.0–21.6% increase | |
| Paternal-series exploratory activity | 94.5–109.9% increase | p<0.05 |
| Paternal-series grooming | 26.9–63.5% decrease | p<0.05 |
Different parental-exposure series are not pooled; some reproductive data may overlap the related publication.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Reproductive reports use different exposure schedules and endpoints; possible overlap and formulation details require comparison with the original papers.
Reviewed 2026-10-07.
2000 · [An acute toxicity study of bromantane].
[An acute toxicity study of bromantane].
Bugaeva LI, Verovskiĭ VE, Iezhitsa IN, Spasov AA · Eksperimental'naia i klinicheskaia farmakologiia; 2000 Jan-Feb
Acute animal toxicity testing characterized dose-dependent behavioral effects. The authors proposed different catecholaminergic and cholinergic contributions at different exposures.
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2001 · [Complex evaluation of the effect of bromantane on animal behavior].
[Complex evaluation of the effect of bromantane on animal behavior].
Bugaeva LI, Verovskiĭ VE, Iezhitsa IN, Kuzubova EA, Spasov AA · Eksperimental'naia i klinicheskaia farmakologiia; 2001 Sep-Oct
The authors applied statistical methods to rat open-field behavior to evaluate neurological toxicity. The abstract does not provide a numerical effect estimate.
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
1999 · [The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reaction].Anxiety/activity behaviors: Strain-dependent effects reported
[The effect of bromantane on the behavior of inbred mouse strains with different phenotypes of emotional stress reaction].
Seredenin SB, Miramedova AG, Kozlovskaia MM · Eksperimental'naia i klinicheskaia farmakologiia; 1999 May-Jun
Bromantan altered open-field and elevated-plus-maze behavior differently across mouse strains, supporting a strain-dependent anxiolytic-like response.
Results and tables
Reported findings and study design
BALB/c and C57BL mouse behavior tests; oral Bromantane 40–50 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anxiety/activity behaviors | Strain-dependent effects reported | No numerical scores supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
1999 · [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals].Mouse IP LD50: 8,100 mg/kg
[The characteristics of the neuropsychotropic activity of bromantane in laboratory animals].
Morozov IS, Klimova NV, Karpova TD, Shestopalov SS · Eksperimental'naia i klinicheskaia farmakologiia; 1999 Mar-Apr
The report describes behavioral activation, EEG changes and learning-related effects in laboratory animals.
Results and tables
Reported findings and study design
Animal behavioral/pharmacology study; mouse acute toxicity measured after IP injection.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mouse IP LD50 | 8,100 mg/kg | |
| Behavior and EEG | Stimulation described | No numerical performance change supplied |
Species and administration route are essential to interpreting an LD50; this is not a human exposure limit.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
1997 · Bromontan, a new doping agent.
Bromontan, a new doping agent.
Burnat P, Payen A, Le Brumant-Payen C, Hugon M, Ceppa F · Lancet (London, England); 1997 Sep
Bibliographic record located. The original paper is needed before its findings can be summarized.
- Population / setting
- Not established from the available record
- Source reviewed
- Indexed citation checked; no abstract or full text reviewed. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Original full text and detailed methods have not been reviewed.
- No abstract was available in the retrieved record; no efficacy or safety finding is assigned.
Reviewed 2026-10-07.
2012 · [Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].Subjective response by EEG pattern: Ladasten and placebo responses varied with baseline alpha-rhythm pattern
[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].
Neznamov GG, Bochkarev VK, Reutova MA, Shabanova AA, Siuniakov SA · Eksperimental'naia i klinicheskaia farmakologiia; 2012
Subjective and objective responses to Ladasten and placebo differed across EEG-defined neurasthenia subgroups. Higher subjective responses were not confined to active treatment.
Results and tables
Reported findings and study design
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Subjective response by EEG pattern | Ladasten and placebo responses varied with baseline alpha-rhythm pattern |
The available report gives no numerical treatment effect or enrollment count and identifies no validated predictor of individual response. It is unclear whether earlier EEG reports included some of the same participants.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- Patients; see abstract scope
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- The abstract omits group sizes, assignment, blinding and numerical outcomes; the report cannot establish effects in healthy users.
- This report may share participants with other Ladasten studies on neurasthenia.
Reviewed 2026-10-07.
2011 · Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome.TNF-α/IL-6 and behavior: Ladasten favored in the authors’ comparison
Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome.
Tallerova AV, Kovalenko LP, Durnev AD, Durnev AD, Seredenin SB · Bulletin of experimental biology and medicine; 2011 Nov
In an LPS-induced mouse model, Ladasten reduced elevated TNF-alpha and IL-6 and attenuated behavioral disturbances. This is distinct from a clinical depression trial.
Results and tables
Reported findings and study design
Mouse LPS model: LPS 100 micrograms/kg IP; Ladasten 30 or 50 mg/kg for five administrations, versus imipramine 10 mg/kg. LPS one hour after last treatment; measurements two hours later.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| TNF-α/IL-6 and behavior | Ladasten favored in the authors’ comparison | No numerical cytokine concentrations supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2012 · [Effect of ladasten on antenatal and postnatal development].
[Effect of ladasten on antenatal and postnatal development].
Bugaeva LI, Denisova TD, Spasov AA · Eksperimental'naia i klinicheskaia farmakologiia; 2012
The authors reported fewer resorptions and accelerated offspring development after exposure in pregnant rats. These outcomes do not establish pregnancy safety in people.
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Reproductive reports use different exposure schedules and endpoints; possible overlap and formulation details require comparison with the original papers.
Reviewed 2026-10-07.
2011 · [Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].Self-rated tolerability: Comparable with placebo
[Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients].
Reutova MA, Siuniakov SA, Siuniakov TS, Dorofeeva OA, Mametova LÉ, Neznamov GG · Eksperimental'naia i klinicheskaia farmakologiia; 2011
Patients with neurasthenia rated single-dose Ladasten tolerability similarly to placebo. The authors examined associations between self-ratings, baseline characteristics and subsequent treatment response.
Results and tables
Reported findings and study design
Neurasthenia comparison: single Ladasten dose 15 mg versus placebo.
Dose, route and schedule
The indexed abstract reports a single 15 mg dose of Ladasten compared with placebo in patients with neurasthenia. Route is not specified; this single-dose experiment is separate from longer-course Ladasten studies.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Self-rated tolerability | Comparable with placebo | No numerical rate or sample size given |
The indexed abstract prints 15 mg. No dose has been silently substituted.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Patients; see abstract scope
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- The abstract omits group sizes, assignment, blinding and numerical outcomes; the report cannot establish effects in healthy users.
- This report may share participants with other Ladasten studies on neurasthenia.
Reviewed 2026-10-07.
2012 · Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases.Measured biochemical/electrophysiological response: Changes described
Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases.
Salimgareeva MKh, Yamidanov RS, Vakhitova YV, Seredenin SB · Bulletin of experimental biology and medicine; 2012 Jan
The study examined ERK signaling and neurotrophin gene expression in rat brain regions after Ladasten. The abstract does not state the direction or magnitude of the individual results.
Results and tables
Reported findings and study design
Single Ladasten 50 mg/kg in rat brain; ERK activity and neurotrophin gene expression.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Measured biochemical/electrophysiological response | Changes described | No numerical effect magnitude supplied in the indexed abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2011 · [Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice].Cytokines, behavior and immune-organ indices: Ladasten favored in the authors’ comparison
[Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice].
Tallerova AV, Kovalenko LP, Durnev AD, Seredenin SB · Eksperimental'naia i klinicheskaia farmakologiia; 2011
In socially stressed male mice, Ladasten reduced selected inflammatory cytokines and attenuated behavioral and immune-organ changes.
Results and tables
Reported findings and study design
Mouse social-stress model: Ladasten 30 mg/kg IP versus imipramine 10 mg/kg; single treatment after three stress days or five-day treatment after ten stress days. Measures 24 hours after last injection.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cytokines, behavior and immune-organ indices | Ladasten favored in the authors’ comparison | No numerical effect sizes supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
1995 · [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain].Serotonin/metabolites: Region-dependent increases and decreases
[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain].
Kudrin VS, Sergeeva SA, Krasnykh LM, Miroshnichenko II, Grekhova TV, Gaĭnetdinov RR · Eksperimental'naia i klinicheskaia farmakologiia; 1995 Jul-Aug
Acute and chronic exposure altered serotonin and dopamine-related measures across rat brain regions, with different regional directions of response.
Results and tables
Reported findings and study design
Rat monoamine experiments with acute/chronic oral Bromantane 50 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Serotonin/metabolites | Region-dependent increases and decreases | No numerical concentration changes supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2010 · [Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].Afobazole-only serotonin changes: 5-HT up to +50%, precursor up to +60%, metabolite up to +50%
[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].
Davydova AI, Klodt PM, Kudrin VS, Kuznetsova EA, Narkevich VB · Eksperimental'naia i klinicheskaia farmakologiia; 2010 Mar
Under experimental blockade of monoamine synthesis, Ladasten increased L-DOPA in several rat brain regions and altered dopamine-metabolism indices. Effects differed from the afobazole comparator.
Results and tables
Reported findings and study design
Rat monoamine-synthesis-blockade experiment comparing Ladasten and Afobazole.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Afobazole-only serotonin changes | 5-HT up to +50%, precursor up to +60%, metabolite up to +50% | These percentages are NOT Ladasten effects |
| Ladasten L-DOPA/dopamine pathway | Changes described across brain regions | No numerical Ladasten-specific increase supplied |
Comparator percentages are labeled explicitly to prevent attribution to Bromantane.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2010 · Proteomic analysis and identification of ladasten target proteins in rat brain.Proteins identified with differing expression: 13
Proteomic analysis and identification of ladasten target proteins in rat brain.
Yamidanov RS, Salimgareeva MKh, Sadovnikov SV, Vakhitova YV, Govorun VM, Seredenin SB · Bulletin of experimental biology and medicine; 2010 Nov
Proteomic analysis identified 13 rat-brain proteins with altered expression after a single Ladasten exposure. Identification of expression changes does not establish direct drug binding to those proteins.
Results and tables
Reported findings and study design
Rat-brain proteomic experiment after single Ladasten 50 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Proteins identified with differing expression | 13 | Identification count, not a clinical benefit measure |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2010 · [Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb].Dopamine-transport inhibition IC50: Ladasten 3.56 microM; Sydnocarb 28.66 nM
[Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb].
Zimin IA, Abaimov DA, Budygin EA, Zolotarev IuA, Kovalev GI · Eksperimental'naia i klinicheskaia farmakologiia; 2010 Feb
The experiments found no direct effects on the tested dopamine and serotonin receptors, but reported increased dopamine synthesis and release and inhibition of dopamine transport in rat preparations.
Results and tables
Reported findings and study design
Rat-brain assays and single-dose Ladasten 50 mg/kg IP or Sydnocarb 17.5 mg/kg IP.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dopamine-transport inhibition IC50 | Ladasten 3.56 microM; Sydnocarb 28.66 nM | Different concentration units retained |
| Direct D1/D2/D3 or 5-HT1A/5-HT2A effects | Not detected | |
| Dopamine synthesis/release | Stimulated by Ladasten | No numerical increase supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2011 · [Ladasten in the management of non-motor symptoms of Parkinson's disease].
[Ladasten in the management of non-motor symptoms of Parkinson's disease].
Sarycheva TN, Rybak VA, Kurushina OV · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2011
Bibliographic record located. The original paper is needed before its findings can be summarized.
- Population / setting
- Not established from the available record
- Source reviewed
- Indexed citation checked; no abstract or full text reviewed. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Original full text and detailed methods have not been reviewed.
- No abstract was available in the retrieved record; no efficacy or safety finding is assigned.
Reviewed 2026-10-07.
2010 · [Prospects for using ladasten preparations in patients with irritable bowel syndrome].
[Prospects for using ladasten preparations in patients with irritable bowel syndrome].
Uspenskiĭ IuP, Fominykh IuA · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology; 2010
The abstract describes Ladasten use in patients with irritable bowel syndrome and asthenic symptoms but provides no sample size, comparison details or numerical outcomes.
- Population / setting
- Patients; see abstract scope
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- The abstract omits group sizes, assignment, blinding and numerical outcomes; the report cannot establish effects in healthy users.
Reviewed 2026-10-07.
2008 · [Characteristics of ladasten effect in neurasthenia patients with various EEG parameters].
[Characteristics of ladasten effect in neurasthenia patients with various EEG parameters].
Neznamov GG, Bochkarev VK, Siuniakov SA, Grishin SA · Eksperimental'naia i klinicheskaia farmakologiia; 2008 Jul-Aug
Anxiety-asthenia patients with different EEG alpha-rhythm patterns showed different clinical and EEG responses to Ladasten. The abstract does not establish a validated treatment-selection biomarker.
- Population / setting
- Patients; see abstract scope
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- The abstract omits group sizes, assignment, blinding and numerical outcomes; the report cannot establish effects in healthy users.
- This report may share participants with other Ladasten studies on neurasthenia.
Reviewed 2026-10-07.
2009 · Changes in CREB (SER133) content and DNA-binding activity of transcriptional factors in rat brain cells against the background of ladasten exposure.Measured biochemical/electrophysiological response: Changes described
Changes in CREB (SER133) content and DNA-binding activity of transcriptional factors in rat brain cells against the background of ladasten exposure.
Salimgareeva MKh, Vakhitova YV, Yamidanov RS, Sadovnikov SV, Seredenin SB · Bulletin of experimental biology and medicine; 2009 May
The study examined phosphorylated CREB and transcription-factor DNA-binding activity in rat brain regions. The abstract does not quantify individual effects.
Results and tables
Reported findings and study design
Single Ladasten 50 mg/kg in rat brain; phosphorylated CREB and DNA-binding activity.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Measured biochemical/electrophysiological response | Changes described | No numerical effect magnitude supplied in the indexed abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2007 · The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.Synaptic potentiation: Short-term potentiation converted to longer-lasting form
The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.
Mikhaylova M, Vakhitova JV, Yamidanov RS, Salimgareeva MKh, Seredenin SB, Behnisch T · Neuropharmacology; 2007 Oct
Ladasten altered dopamine-synthesis measures in rats and reinforced short-term synaptic potentiation in hippocampal preparations. Protein-synthesis inhibition blocked this reinforcement; dopamine-receptor antagonism attenuated it.
Results and tables
Reported findings and study design
Single oral Ladasten 50 mg/kg for catecholamine work; hippocampal slice experiments with 10 microM Ladasten.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Synaptic potentiation | Short-term potentiation converted to longer-lasting form | |
| Delayed application | Still effective 40 minutes after stimulation | |
| Stimulation | 100 Hz for 200 ms | |
| Mechanistic blockade | Protein-synthesis inhibition blocked reinforcement | D1/D5 antagonism attenuated it |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2006 · [Pilot clinical trial of ladasten].
[Pilot clinical trial of ladasten].
Siuniakov SA, Grishin SA, Teleshova ES, Neznamov GG, Seredenin SB · Eksperimental'naia i klinicheskaia farmakologiia; 2006 Jul-Aug
An early clinical report describes stimulant and anxiolytic effects in patients with psychogenic asthenia. The abstract does not provide sample size, allocation details or numerical treatment effects.
- Population / setting
- Patients; see abstract scope
- Source reviewed
- Indexed abstract and original publisher metadata checked. The publisher PDF route was located, but its full article could not be inspected; no numerical result has been inferred.
Study limitations
- Original full text and detailed methods have not been reviewed.
- The abstract omits group sizes, assignment, blinding and numerical outcomes; the report cannot establish effects in healthy users.
- This report may share participants with other Ladasten studies on neurasthenia.
Reviewed 2026-11-05.
2006 · [Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].
[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].
Vakhitova IuV, Sadovnikov SV, Iamidanov RS, Seredenin SB · Genetika; 2006 Jul
After a single Ladasten exposure, rat hypothalamic cells showed increased cytosine demethylation at selected regulatory sites of the tyrosine-hydroxylase gene. The authors proposed a connection with increased transcription.
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2006 · [Thermoprotector properties of a combination of sydnocarb with ladasten].Thermoprotector response: Significant with 20 + 20 mg/kg
[Thermoprotector properties of a combination of sydnocarb with ladasten].
Levina MN, Badyshtov BA, Gan'shina TS · Eksperimental'naia i klinicheskaia farmakologiia; 2006 Jan-Feb
A Sydnocarb–Ladasten combination showed thermoprotective effects and increased cerebral blood flow and respiration in experimental animals.
Results and tables
Reported findings and study design
Animal heat model: 1:1 Ladasten/Sydnocarb combinations at 10 or 20 mg/kg of each component.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thermoprotector response | Significant with 20 + 20 mg/kg | Numerical survival/temperature effect size not supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Combination results apply only to the tested model; separate studies do not establish a safe human combination or ratio.
Reviewed 2026-10-07.
2006 · [Comparative study of the effect of Ladasten, Sydnocarb and their combination on physical work ability of laboratory animals].Work-capacity response: Individual drugs outperformed their combination
[Comparative study of the effect of Ladasten, Sydnocarb and their combination on physical work ability of laboratory animals].
Levina MN, Badyshtov BA, Iarkova MA · Eksperimental'naia i klinicheskaia farmakologiia; 2006 May-Jun
In a mouse swimming test, the individual drugs produced more pronounced and longer-lasting performance effects than the Ladasten–Sydnocarb combination. The result does not support universal combination synergy.
Results and tables
Reported findings and study design
Mouse swimming comparison of Ladasten, Sydnocarb or combination at 10 and 20 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Work-capacity response | Individual drugs outperformed their combination | More pronounced and prolonged responses; swimming-time values absent |
This experiment does not support universal combination synergy.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Combination results apply only to the tested model; separate studies do not establish a safe human combination or ratio.
Reviewed 2026-10-07.
2004 · [The effect of ladasten on the activation-induced expression of Fas receptor on T-lymphocytes and their sensitivity to Fas-induced apoptosis].TCR-linked proliferation and ERK2: Comitogenic effect reported
[The effect of ladasten on the activation-induced expression of Fas receptor on T-lymphocytes and their sensitivity to Fas-induced apoptosis].
Vakhitova IuV, Salimgareeva MKh, Sibiriak SV, Kurchatova NN, Seredin SB · Eksperimental'naia i klinicheskaia farmakologiia; 2004 Sep-Oct
In human peripheral-blood T cells, Ladasten increased selected activation-related responses and reduced Fas-induced apoptosis, while largely leaving activation-induced Fas expression unchanged.
Results and tables
Reported findings and study design
Human peripheral-blood T-cell cultures; Ladasten 0.1–10 microM.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| TCR-linked proliferation and ERK2 | Comitogenic effect reported | |
| Fas-induced apoptosis | Reduced | Numerical cell-fraction changes absent |
| Fas-receptor expression | Virtually unchanged |
Human-derived cells are not a clinical immune-treatment study.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Human T-cell preparations
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2005 · [Studying the mechanisms of ladasten action].Anxiety-related behavior: Effect in MR rats; no effect in MNRA rats
[Studying the mechanisms of ladasten action].
Iarkova MA, Voronin MV, Seredenin SB · Eksperimental'naia i klinicheskaia farmakologiia; 2005 May-Jun
Ladasten produced an anxiolytic-like effect in one rat stress-response phenotype but not the other, and prevented stress-related changes in benzodiazepine-site binding in the responsive strain.
Results and tables
Reported findings and study design
Two rat stress-response phenotypes, MR and MNRA; Ladasten 30 mg/kg IP.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anxiety-related behavior | Effect in MR rats; no effect in MNRA rats | |
| Stress-related benzodiazepine-site changes | Prevented in responsive phenotype | Numerical binding changes absent |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2005 · Psychotropic effects of sidnocarb and ladasten in inbred mice with different reaction to emotional stress.Ladasten tested dose: 10 mg/kg
Psychotropic effects of sidnocarb and ladasten in inbred mice with different reaction to emotional stress.
Levina MN · Bulletin of experimental biology and medicine; 2005 Mar
Behavioral effects varied by mouse strain and exposure. Ladasten alone and in combination with Sidnocarb produced different patterns of activation.
Results and tables
Reported findings and study design
BALB/c and C57BL/6 mouse behavior experiments.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ladasten tested dose | 10 mg/kg | |
| Combination | Ladasten 10 mg/kg plus Sydnocarb 6 or 12 mg/kg | |
| Response | Phenotype-dependent activation/anxiety effects | Numerical behavior scores absent |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
- Combination results apply only to the tested model; separate studies do not establish a safe human combination or ratio.
Reviewed 2026-10-07.
2002 · Toxic effect of single treatment with bromantane on neurological status of experimental animals.Behavioral stimulation range: 30–300 mg/kg
Toxic effect of single treatment with bromantane on neurological status of experimental animals.
Iezhitsa IN, Spasov AA, Bugaeva LI, Morozov IS · Bulletin of experimental biology and medicine; 2002 Apr
Acute rat testing showed stimulation at lower tested exposures and behavioral suppression and other toxicity signs at higher exposures. Temperature and sensory responses also changed.
Results and tables
Reported findings and study design
Rat acute-neurotoxicity observations using the Irwin test battery.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Behavioral stimulation range | 30–300 mg/kg | |
| Behavioral suppression range | 600–9,600 mg/kg | |
| Spontaneous activity | Increased at 30–300; unchanged at 600; inhibited above 600 mg/kg | |
| Pain thresholds | Lower at 300–600; higher above 600 mg/kg | |
| Blepharoptosis | Above 10 g/kg | |
| Respiratory changes | Above 5 g/kg | |
| Rectal temperature | Decrease of 0.5–1 °C at virtually all doses |
These are animal toxicity observations, not human dose boundaries.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal or animal-tissue experiments
- Source reviewed
- Indexed citation and English abstract checked.
Study limitations
- Original full text and detailed methods have not been reviewed.
- Experimental findings do not establish human efficacy, dosing or long-term safety.
Reviewed 2026-10-07.
2005 · The effect of ladasten on gene expression in the rat brain.
The effect of ladasten on gene expression in the rat brain.
Vakhitova YV, Yamidanov RS, Vakhitov VA, Seredenin SB · Doklady. Biochemistry and biophysics; 2005 Mar-Apr
Bibliographic record located. The original paper is needed before its findings can be summarized.
- Population / setting
- Not established from the available record
- Source reviewed
- Indexed citation checked; no abstract or full text reviewed. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Original full text and detailed methods have not been reviewed.
- No abstract was available in the retrieved record; no efficacy or safety finding is assigned.
Reviewed 2026-10-07.
1998 · [Comparative analysis of effects of adapromine, midantan, and bromantane on the bioelectric activity of the rat brain].
[Comparative analysis of effects of adapromine, midantan, and bromantane on the bioelectric activity of the rat brain].
Krapivin SV, Sergeeva SA, Morozov IS · Biulleten' eksperimental'noi biologii i meditsiny; 1998 Feb
Bibliographic record located. The original paper is needed before its findings can be summarized.
- Population / setting
- Not established from the available record
- Source reviewed
- Indexed citation checked; no abstract or full text reviewed. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Original full text and detailed methods have not been reviewed.
- No abstract was available in the retrieved record; no efficacy or safety finding is assigned.
Reviewed 2026-10-07.
1999 · [Analysis of pharmacological properties of bromantane].
[Analysis of pharmacological properties of bromantane].
Seredenin SB, Miramedova AG · Biulleten' eksperimental'noi biologii i meditsiny; 1999 Nov
Bibliographic record located. The original paper is needed before its findings can be summarized.
- Population / setting
- Not established from the available record
- Source reviewed
- Indexed citation checked; no abstract or full text reviewed. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Original full text and detailed methods have not been reviewed.
- No abstract was available in the retrieved record; no efficacy or safety finding is assigned.
Reviewed 2026-10-07.
1995 · [Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane].
[Correlated interconnection between pharmacokinetic and dynamic development of the pharmacologic effects of bromantane].
Sergeeva SA, Krapivin SV, Losev AS, Morozov IS · Biulleten' eksperimental'noi biologii i meditsiny; 1995 Mar
Bibliographic record located. The original paper is needed before its findings can be summarized.
- Population / setting
- Not established from the available record
- Source reviewed
- Indexed citation checked; no abstract or full text reviewed. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Original full text and detailed methods have not been reviewed.
- No abstract was available in the retrieved record; no efficacy or safety finding is assigned.
Reviewed 2026-10-07.
1995 · [The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study].
[The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study].
Grekhova TV, Gaĭnetdinov RR, Sotnikova TD, Krasnykh LM, Kudrin VS, Sergeeva SA, Morozov IS · Biulleten' eksperimental'noi biologii i meditsiny; 1995 Mar
Bibliographic record located. The original paper is needed before its findings can be summarized.
- Population / setting
- Not established from the available record
- Source reviewed
- Indexed citation checked; no abstract or full text reviewed. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Original full text and detailed methods have not been reviewed.
- No abstract was available in the retrieved record; no efficacy or safety finding is assigned.
Reviewed 2026-10-07.
2019 · Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperaturesCold-exposure motor coordination: 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls
Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures
Format: Patent · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
· RU2704126C2; filed 28 November 2016
The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.
Results and tables
Reported patent results
Reported findings
The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.
Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cold-exposure motor coordination | 24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controls | Medians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control |
| Sydnocarb comparator | 6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold control | Worse retention in this test; not general clinical inferiority · p=0.04 |
These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure.
- The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product.
- The groups were small, and the source gives conflicting comparison-group sizes.
Reviewed 2026-11-06.
2022 · Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Format: Journal article; full-text reproduction · Reviewed: Abstract, identity passage and selected methods reviewed
N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev · Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
- Population / setting
- CD-1 mice separated by baseline attention phenotype; three administrations
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
- Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.
Reviewed 2026-10-03.
2023 · Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
- Population / setting
- Mouse pharmacology experiments
- Source reviewed
- Institute abstract and selected author-uploaded full-text passages checked, including the 7/14-day schedule and baseline-imbalance discussion; complete tables not independently appraised.
Study limitations
- Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
- An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
- The Russian and English versions are one publication, not independent replication.
Reviewed 2026-10-03.
· Role of neurotropic adamantane-containing compounds in the regulation of immunity
Role of neurotropic adamantane-containing compounds in the regulation of immunity
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
· Dissertation author’s abstract; third-party Russian transcription
The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.
- Population / setting
- Multiple mouse strains and laboratory immune assays
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
- Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.
Reviewed 2026-10-03.
1996 · Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996
ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
- Population / setting
- Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Original structures and tables require checking against the scan; transcription errors are possible.
- Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
- Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.
Reviewed 2026-10-03.
1996 · Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulationOriginal experimental outcomes: Not available in the accessed bibliographic entry
Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation
· SU1646256A1
The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.
Results and tables
Reported patent results
Experimental results unavailable in the accessed source
Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.
The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Original experimental outcomes | Not available in the accessed bibliographic entry | No animal survival percentage or human performance effect is invented |
This is an access gap, not proof that the original certificate contained no experiments. Obtain the original publication before entering quantitative findings.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
- Source reviewed
- Bibliographic index entry accessed. No readable original experimental description or results tables were available; quantitative extraction requires the original publication.
Study limitations
- Only the patent abstract and metadata were recovered; the two experimental tables remain unavailable.
- Abstract toxicity figures lack adequate species/route context here and are not used to rank safety.
Reviewed 2026-11-06.
2016 · Potential synthetic adaptogens I: new N-[(adamantan-1-yl)methyl]aniline derivatives
Potential synthetic adaptogens I: new N-[(adamantan-1-yl)methyl]aniline derivatives
· Russian Chemical Bulletin. 65:1336–1340
The authors prepared more conformationally flexible Bromantane analogues and studied how reaction conditions affected products and yields.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
2017 · Potential Synthetic Adaptogens II: synthesis and pharmacological activity of conformationally labile Bromantane analogues
Potential Synthetic Adaptogens II: synthesis and pharmacological activity of conformationally labile Bromantane analogues
· Pharmaceutical Chemistry Journal. 50:781–787
Bibliographic record for the N-[(adamantan-1-yl)methyl]-4-bromoaniline series. Compound-specific pharmacological results await full-text appraisal.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
2017 · Potential Synthetic Adaptogens IV: synthesis and study of basicity of new N-[(adamantan-1-yl)methyl]aniline derivatives
Potential Synthetic Adaptogens IV: synthesis and study of basicity of new N-[(adamantan-1-yl)methyl]aniline derivatives
· Russian Journal of Organic Chemistry. 53(5):663–672
Publisher contents identify the basicity study. Brain penetration and clinical activity cannot be inferred from basicity measurements.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
2019 · Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction
Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction
· Zhurnal Organicheskoi Khimii. 55(11):1781–1788
Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Chemistry and preclinical observations do not establish human efficacy or safety.
Reviewed 2026-10-03.
2024 · Psychotropic activity of N-(camphan-2-yl)anilines: new structural analogues of Bromantane
Psychotropic activity of N-(camphan-2-yl)anilines: new structural analogues of Bromantane
· Pharmacy & Pharmacology. 12(4):295–308
The Russian abstract identifies para-ethylphenyl compound 4e as a lead with anxiolytic-like activity and signals in novel-object recognition and extrapolation-escape tests in rodents.
- Population / setting
- Preclinical research; no human efficacy established
- Source reviewed
- Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
- Russian abstract and bibliography checked, not the complete experimental tables.
- This record follows the Russian 4e designation; the compound numbers in the two languages still need to be checked against the chemical structures. No human benefit or superiority is established.
Reviewed 2026-10-03.
2009 · Ladasten in neurasthenia and somatogenic asthenia: safety and therapeutic efficacySymptom improvement: Reported over 28 days
Ladasten in neurasthenia and somatogenic asthenia: safety and therapeutic efficacy
Format: Publisher HTML article · Reviewed: Methods, results and harms narrative
A. S. Avedisova, T. Yu. Kulikova, O. I. Mikhailova · Mental Disorders in General Medicine. 2009(1):57–60
Single-blind, stratified randomized comparison reported symptom improvement over 28 days. Mild restlessness during treatment and transient dizziness after withdrawal were reported.
Results and tables
Reported findings and study design
40 patients: 20 with each of two diagnoses, randomized within diagnosis to active drug or placebo; four cells of ten. Single-blind, 28-day treatment and seven-day post-treatment observation.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Symptom improvement | Reported over 28 days | Numerical table values were not transcribed in the prior review |
| Harms described | Mild restlessness during treatment; transient dizziness after withdrawal | Event denominators not supplied in the checked narrative |
Existing publisher methods and narrative review used. Table recovery is deferred; possible overlap with other 2009 reports remains unresolved.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 40 patients: 20 per diagnosis, randomized within diagnosis to active treatment or placebo (10 per cell)
- Source reviewed
- Publisher methods, results and harms narrative checked; image tables not independently transcribed.
Study limitations
- Four small groups; multiple symptom outcomes.
- Seven-day post-treatment observation cannot establish long-term dependence or safety.
- Overlap with other 2009 Ladasten reports remains unresolved; do not sum cohorts.
Reviewed 2026-10-02.
1995 · Pharmacokinetics of adamantane-derived actoprotectors: Bromitil experiments
Pharmacokinetics of adamantane-derived actoprotectors: Bromitil experiments
· Dissertation transcription
Format: Dissertation excerpt transcription · Reviewed: Contents and reproduced conclusions
L. M. Krasnykh · Candidate dissertation, Kupavna, 1995
The dissertation contents and reproduced conclusions identify a Bromitil pharmacokinetic section. The formulation is discussed as combined Bromantane and Bemitil.
- Population / setting
- Experimental pharmacokinetic program; rat studies
- Source reviewed
- Third-party transcription of original dissertation contents and conclusions checked; complete 162-page dissertation not recovered.
Study limitations
- Transcription is not a verified original scan.
- Pharmacokinetic interaction does not demonstrate clinical synergy or combination safety.
- Exact formulation and experiment-level denominators require the original methods.
Reviewed 2026-10-02.
2009 · Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)]Treatment completion: 15/15 active group versus 7/15 placebo group
Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)]
Format: Journal article reproduction · Reviewed: Methods, attrition and selected tables
Neznamov GG, Siuniakov SA, Teleshova SE, Chumakov DV, Reutova MA, Siuniakov TS, Mametova LE, Dorofeeva OA, Grishin SA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 109(5):20-26. PMID 19491814
Single-blind randomized placebo comparison reported symptom improvement. All active-treatment patients completed; only seven placebo participants completed. Missing values were handled using last observation carried forward.
Results and tables
Reported findings and study design
Thirty neurasthenia patients randomized 15/15; 28 days of single-blind treatment plus one-week follow-up.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Treatment completion | 15/15 active group versus 7/15 placebo group | |
| Missing-outcome handling | Last observation carried forward | Differential dropout may distort symptom comparisons |
Values are from the previously checked article reproduction. Overlap with other 2009 Ladasten reports remains unresolved.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 30 patients with neurasthenia; 15 per arm
- Source reviewed
- Original article text reproduced on ResearchGate checked, including randomization and attrition passages; independent statistical reanalysis not performed.
Study limitations
- Differential attrition and last-observation-carried-forward analysis can bias estimates.
- Small single-blind comparison with 28-day treatment and one-week follow-up.
- No long-term absence-of-dependence conclusion follows.
- Overlap with related 2009 reports remains unresolved.
Reviewed 2026-10-02.
2010 · Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]CGI-S responders: 76.0%
Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]
· Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 110(5 Suppl 1):17-26. PMID 20559263
Reports symptom and quality-of-life improvements during 28 days of Ladasten treatment and follow-up. The abstract reports adverse events in 3% and discontinuation in 0.8%.
Results and tables
Reported findings and study design
Uncontrolled multicenter report: 28 centers, 728 analyzed patients (91.6% of the enrolled sample). Ladasten 50–100 mg/day for 28 days; follow-up one month after treatment.
Dose, route and schedule
Ladasten (bromantane): 50–100 mg/day for 28 days. The indexed abstract does not specify the route or how the daily dose was divided.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CGI-S responders | 76.0% | |
| CGI-I responders | 90.8% | |
| First reported antiasthenic effect | Day 3 | |
| Adverse effects | 3% | |
| Stopped therapy | 0.8% | |
| Serious adverse effects | None reported in this cohort |
Responder percentages use different CGI scales. There is no concurrent placebo comparison in the abstract; the results are not independent of duplicate reports of this cohort.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 728 analyzable patients with psychoautonomic syndrome in 28 Russian centers
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- No concurrent comparator is described in the abstract; improvement alone does not establish causality.
- PMID 21322821 has the same title, cohort and abstract: treat it as a related report of this cohort, not independent replication.
- Short follow-up and incomplete ascertainment cannot rule out uncommon or long-term harms.
Reviewed 2026-09-29.
2009 · Effect of ladasten on the psychophysiological parameters of healthy volunteers]Psychophysiological performance: Improvement reported during mental fatigue
Effect of ladasten on the psychophysiological parameters of healthy volunteers]
Bogdan NG, Kolotilinskaia NV, Iarkova MA, Nadorov SA, Badyshtov BA, Seredenin SB · Eksperimental'naia i klinicheskaia farmakologiia 72(3):3-9. PMID 19642584
The authors report psychophysiological changes during mental fatigue, with larger effects in stress-labile participants.
Results and tables
Reported findings and study design
Healthy-volunteer mental-fatigue experiment; single Ladasten dose 100 mg.
Dose, route and schedule
Ladasten (bromantane): a single 100 mg administration in healthy volunteers. The indexed abstract does not specify the route.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Psychophysiological performance | Improvement reported during mental fatigue | Greater response in stress-labile participants; numerical effect size and group size absent from the abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Healthy volunteers in a laboratory mental-fatigue setting; sample size not in abstract
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Allocation, blinding, enrollment and outcome definitions require the original paper.
- This fatigued setting differs from the neutral principal-performance findings in the 2000 rested-volunteer study.
Reviewed 2026-09-29.
1993 · Experimental rationale for the use of drugs to increase the resistance of the human body to the combined action of carbon monoxide and hyperthermia]Bemitil arm: 0.5 g
Experimental rationale for the use of drugs to increase the resistance of the human body to the combined action of carbon monoxide and hyperthermia]
Sedov AV, Lukicheva TA, Surovtsev NA, Akin'shin AV, Nazarov LIu, Miroshnik SV · Meditsina truda i promyshlennaia ekologiia (9-10):10-11. PMID 8087458
Compared placebo, Bemitil, Bromantane and their combination. The abstract favors Bromantane-containing groups under the experimental exposure.
Results and tables
Reported findings and study design
Volunteer comparison under heat and gas exposure; ambient 50 ± 2 °C, relative humidity 20 ± 5%, gas concentration 300 mg/m³.
Dose, route and schedule
Experimental exposure comparison: Bemitil 0.5 g, bromantane 0.25 g, their combination, or placebo. The indexed abstract does not specify a route or repeat-dose schedule. These experimental conditions do not establish protection during real-world hazardous work.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Bemitil arm | 0.5 g | |
| Bromantane arm | 0.25 g | |
| Combination arm | Bemitil 0.5 g + Bromantane 0.25 g | |
| Best-performing arms as described | Bromantane and the combination | Numerical effect magnitude not supplied |
The English abstract says carbon dioxide; other source descriptions say monoxide. Gas identity remains unresolved. This is an exposure experiment, not protection guidance.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Volunteers exposed to a combined heat and gas model; enrollment not given
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- The title identifies carbon monoxide, while the English abstract says carbon dioxide: the original Russian methods are needed to resolve this inconsistency.
- Randomization, blinding and effect sizes are not established by the abstract.
- Not evidence that toxic or heat exposure is safe, or a substitute for exposure controls.
Reviewed 2026-09-29.
2014 · Possibilities of the pharmacological correction of adaptive reactions of human organism in short-term moving from middle to high altitude]Adaptation timing: Combination: within first hours; Hypoxen: by day 3; placebo: still developing on day 3
Possibilities of the pharmacological correction of adaptive reactions of human organism in short-term moving from middle to high altitude]
Kundashev UK, Zurdinov AZ, Barchukov VG · Eksperimental'naia i klinicheskaia farmakologiia 77(9):32-37. PMID 25365868
An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.
Results and tables
Reported findings and study design
An altitude-adaptation comparison reported earlier metabolic adaptation with combined Metaprot and Ladasten than with Hypoxen or placebo. The abstract does not quantify the work-capacity improvement.
Volunteers acclimatized for 15 days at 1,670 m before moving to 3,750 m; group sizes not supplied.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Adaptation timing | Combination: within first hours; Hypoxen: by day 3; placebo: still developing on day 3 | Authors’ descriptive metabolic time course, not a timed endurance effect |
| Exercise tolerance and blood-cell measures | Reported stronger responses with the combination | No absolute work or blood-cell effect sizes supplied |
| Studied arms | Metaprot 0.125 g + Ladasten 0.1 g; Hypoxen 0.5 g; placebo | Combination effect cannot be assigned to either component alone |
No component-only arms are described in the abstract. Earlier metabolic adaptation does not establish safe high-altitude use or independent bromantane efficacy.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- Volunteers moving from 1,670 m to 3,750 m after 15 days at middle altitude
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- No single-component arms are described, so the study cannot isolate contributions or establish synergy.
- Enrollment and allocation details require full-text review.
- Not a validated altitude-illness prevention strategy.
Reviewed 2026-11-01.
1995 · Study of heat-protective effects of bromantane at various levels of overheating
Study of heat-protective effects of bromantane at various levels of overheating
Badyshtov BA, Losev AS, Makhnycheva AL, Barchukov VG, Sytnik SI, Pastushenkov VA, Kolotilinskaia NV, Mironov SA, Morozov IS, Seredenin SB · Voprosy meditsinskoi khimii 41(2):54-57. PMID 7793100
The abstract describes model-dependent heat responses, including narrowed heat-tolerance ranges alongside favorable dynamometry and hemodynamic findings under a different heat-load setting.
- Population / setting
- Overheating and exercise in heat. The available summary does not identify who or what was studied.
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised. Evidence category checked against indexed publication types, population indexing and available abstract on 2026-10-16; this does not imply full-text methods appraisal.
Study limitations
- Duplicate catalogue entry consolidated; this is one publication.
- Mixed heat-tolerance wording requires original-language full-text appraisal.
- No general claim of protection from heat injury or occupational exposure follows.
Reviewed 2026-10-02.
1998 · The effect of bromantane on the physical work capacity of laboratory animals]Physical-work performance: 1.3–1.6 times the effect of optimal-dose phenamine
The effect of bromantane on the physical work capacity of laboratory animals]
Morozov IS, Kleĭmenova NN · Eksperimental'naia i klinicheskaia farmakologiia 61(6):51-53. PMID 9929819
Reports sustained physical-performance changes and less mitochondrial alteration following repeated extreme exercise.
Results and tables
Reported findings and study design
Mouse and rat swimming/treadmill experiments; Bromantane 0.5–50 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Physical-work performance | 1.3–1.6 times the effect of optimal-dose phenamine | Animal experiment |
| Duration of effect | At least 24 hours |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Mice and rats in swimming, treadmill and repeated-load experiments
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Animal endurance endpoints do not establish human benefit.
- Comparisons with phenamine do not establish general superiority or safety.
Reviewed 2026-09-29.
2000 · Effects of bromantane and sidnocarb on long-term operant conditioning and its vegetative correlates in rats]Task accuracy: Fewer errors with Bromantane
Effects of bromantane and sidnocarb on long-term operant conditioning and its vegetative correlates in rats]
Morozov IS, Efimova LP, Salenko IuA · Eksperimental'naia i klinicheskaia farmakologiia 63(3):11-15. PMID 10934588
Bromantane and sydnocarb changed operant performance differently. Bromantane was associated with fewer errors and fewer total responses.
Results and tables
Reported findings and study design
Five-hour operant-task experiment in rats: oral Bromantane 20 mg/kg versus oral Sydnocarb 10 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Task accuracy | Fewer errors with Bromantane | Sydnocarb instead increased the number of responses; raw error counts not printed |
| Cardiovascular functional activation | No change with either drug |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rats performing a five-hour learned operant task
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- An aversively motivated rat task is not a human watchkeeping or workplace-safety trial.
Reviewed 2026-09-29.
1993 · A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]
A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]
Krapivin SV, Sergeeva SA, Morozov IS · Biulleten' eksperimental'noi biologii i meditsiny 116(11):515-518. PMID 8312546
Quantitative EEG analysis describes prolonged, biphasic changes after Bromantane.
- Population / setting
- Freely behaving rats with recordings from several brain regions
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- EEG pattern changes are not proof of improved cognition or occupational safety.
Reviewed 2026-09-29.
2004 · Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain]Measured biochemical/electrophysiological response: Changes described
Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain]
Vakhitova IuV, Iamidanov RS, Seredinin SB · Eksperimental'naia i klinicheskaia farmakologiia 67(4):7-11. PMID 15500036
Reports changes in tyrosine hydroxylase and DOPA-decarboxylase gene expression alongside dopamine and L-DOPA measurements.
Results and tables
Reported findings and study design
Ladasten 50 mg/kg; rat dopamine-synthesis gene/transmitter measurements over time.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Measured biochemical/electrophysiological response | Changes described | No numerical effect magnitude supplied in the indexed abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rat striatum and hypothalamus
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Rat gene-expression findings do not establish lasting dopamine enhancement in humans.
- Brain-region and time-dependent results should not be reduced to a single mechanism.
Reviewed 2026-09-29.
2004 · The effect of ladasten on the activity of cAMP-dependent protein kinases and the phosphorylation of proteins in brain cells of rats]Protein kinase A activity: Increase reported
The effect of ladasten on the activity of cAMP-dependent protein kinases and the phosphorylation of proteins in brain cells of rats]
Vakhitova IuV, Salimgareeva MKh, Seredenin SB · Eksperimental'naia i klinicheskaia farmakologiia 67(3):7-9. PMID 15341058
Examines cAMP-dependent kinase activity and phosphorylation during the early period after Ladasten exposure.
Results and tables
Reported findings and study design
Rat-brain Ladasten experiment: 50 mg/kg; measurements during hours 1–12.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Protein kinase A activity | Increase reported | No numerical percentage in the abstract |
| Phosphorylated protein species | 14 kDa myelin isoform and 30 kDa proteolipid | These are molecular masses, not effect sizes |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rat brain protein fractions
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- A biochemical experiment does not establish clinical benefit.
Reviewed 2026-09-29.
2004 · Effect of ladasten on the proteinase C activity in the rat brain cells]Cytosolic protein kinase C activity: More than twofold increase
Effect of ladasten on the proteinase C activity in the rat brain cells]
Vakhitova IuV, Salimgareeva MKh, Seredenin SB · Eksperimental'naia i klinicheskaia farmakologiia 67(2):12-15. PMID 15188752
Examines calcium-dependent signaling and protein kinase C activity after Ladasten.
Results and tables
Reported findings and study design
Rat-brain experiment using Ladasten 50 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cytosolic protein kinase C activity | More than twofold increase | Initial stage after administration; not a cognitive outcome |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rat brain cells / protein fractions
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Mechanistic pathway findings need confirmation in human therapeutic settings.
Reviewed 2026-09-29.
2005 · DNA macroarray analysis of gene expression changes in rat brain after single administration of 2-aminoadamantane compound]
DNA macroarray analysis of gene expression changes in rat brain after single administration of 2-aminoadamantane compound]
Vakhitova IuV, Iamidanov RS, Vakhitov VA, Seredenin SB · Molekuliarnaia biologiia 39(2):276-285. PMID 15856951
Reports altered expression of a subset of genes related to signaling, cytoskeleton, synaptic proteins and metabolism.
- Population / setting
- Rat brain cDNA-array study with RT-PCR follow-up
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Exploratory gene-expression changes are not demonstrated human neuroplasticity or treatment effects.
Reviewed 2026-09-29.
2011 · Time course of histone deacetylase 1 and acetylated H3 and H4 histones in the brain of rats treated with ladastenMeasured biochemical/electrophysiological response: Changes described
Time course of histone deacetylase 1 and acetylated H3 and H4 histones in the brain of rats treated with ladasten
Salimgareeva MKh, Sadovnikov SV, Yamidanov RS, Vakhitova YV, Seredenin SB · Bulletin of experimental biology and medicine 150(5):603-606. PMID 22235395
Reports changes in HDAC1 and acetylated histones after a single Ladasten exposure.
Results and tables
Reported findings and study design
Single intragastric Ladasten 50 mg/kg; rat HDAC1/histone-acetylation measurements.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Measured biochemical/electrophysiological response | Changes described | No numerical effect magnitude supplied in the indexed abstract |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rat striatum, hippocampus and hypothalamus
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- This does not establish beneficial or persistent epigenetic changes in humans.
Reviewed 2026-09-29.
2002 · Effect of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes ]Comitogenic concentration range: 0.01–1 microM as printed
Effect of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes ]
Vakhitova IuV, Sibiriak SV, Kurchatova NN, Seredenin SB · Eksperimental'naia i klinicheskaia farmakologiia 65(6):49-52. PMID 12596534
Studies proliferation and resistance to chemically induced apoptosis in cultured T cells.
Results and tables
Reported findings and study design
Activated human T-cell cultures for 72 hours; Ladasten tested over 0.1–10 microM, with a separately stated comitogenic range of 0.01–1 microM.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Comitogenic concentration range | 0.01–1 microM as printed | |
| Caspase-3/late apoptosis/bcl-2 | Unchanged | |
| p53 and induced-apoptosis resistance | Changes reported | No numerical expression or surviving-cell fraction supplied |
The two printed concentration ranges are retained separately rather than silently reconciled.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Activated human peripheral-blood T lymphocytes in culture
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Human-derived cells are not a clinical trial; culture concentrations do not establish therapeutic exposure or immune benefit.
Reviewed 2026-09-29.
1999 · The effect of bromantane on the erythro- and leukocytic profile of the peripheral blood in rats]At 30 mg/kg: Higher hemoglobin and leukocytes reported
The effect of bromantane on the erythro- and leukocytic profile of the peripheral blood in rats]
Bugaeva LI, Spasov AA, Morozov IS · Eksperimental'naia i klinicheskaia farmakologiia 62(4):40-43. PMID 10513335
Reports exposure-dependent blood changes; higher exposures produced hematologic alterations and liver and spleen findings.
Results and tables
Reported findings and study design
Rat chronic Bromantane exposure at 30, 150 or 600 mg/kg.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| At 30 mg/kg | Higher hemoglobin and leukocytes reported | |
| At 150/600 mg/kg | Initial three-month increase followed by reductions in red/white cells and hemoglobin | |
| Pathology | Reversible blood-cell abnormalities and liver/spleen changes reported |
Chronic animal toxicity findings, not performance-benefit data.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rats during chronic Bromantane exposure
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Preclinical harm evidence cannot be converted directly into a human risk estimate.
- This record is included alongside favorable experiments to avoid a benefits-only selection.
Reviewed 2026-09-29.
2001 · Effects of bromantan on offspring maturation and development of reflexesLitter-size changes by ascending dose: −34.9%, +45.1%, −44.2%
Effects of bromantan on offspring maturation and development of reflexes
Iezhitsa IN, Spasov AA, Bugaeva LI · Neurotoxicology and teratology 23(2):213-222. PMID 11348840
Reports differences in litter size, early survival, growth and behavioral-development measures across exposure groups.
Results and tables
Reported findings and study design
Female rats, 180–200 g, received oral Bromantane 30/150/600 mg/kg daily for 16 days before mating.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Litter-size changes by ascending dose | −34.9%, +45.1%, −44.2% | Middle dose p<0.05 |
| Offspring loss in first three months | 40% at maternal 150 mg/kg versus 20% control | |
| Later death rate | 3–6%; no difference from control reported | |
| Day-7 offspring weight gain | +83.69% at 30 mg/kg; +58.02% at 600 mg/kg | |
| Persistent weight difference at maternal 30 mg/kg | Through day 35 and again days 77–112 | |
| Negative geotaxis | Control day 8; treated groups about 1–2 days earlier | |
| Surface righting | Control day 8; 30 mg/kg day 6; other treated groups day 7 | |
| Cliff/air righting | About one day earlier in the described treated groups | |
| Grasp/limb strength | Increased grasp duration day 15; all pups demonstrated strength day 16 | |
| Open-field behavior at day 40 | Nonsignificant locomotor/exploratory reduction | |
| Passive-avoidance latency 72 hours after training | +259.0%, +175.3%, +160.7% by ascending maternal dose; control +1.8% | p<0.05 for treated increases |
Developmental shifts are not labeled beneficial. Related maternal-exposure figures may overlap the other reproduction report.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Offspring of female rats treated before mating
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- Mixed developmental findings do not establish reproductive safety.
- Do not translate animal exposure levels into human use guidance.
Reviewed 2026-09-29.
1999 · Adamantane derivatives enhancing body's resistance to emergencies
Adamantane derivatives enhancing body's resistance to emergencies
Morozov IS, Klimova NV, Sergeeva SA, Ivanova IA, Barchukov VG, Kovalev GI, Piatin BM, Avdiunina NI · Vestnik Rossiiskoi akademii meditsinskikh nauk (3):28-32. PMID 10222828
Summarizes screening of adamantane derivatives and distinguishes Bromantane from the chemically different Chlodantane.
- Population / setting
- Experimental adamantane-development program and animal stress models
- Source reviewed
- Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Study limitations
- A development-program summary is not an independent human trial.
- Historical claims about specific military deployments need their own contemporary documentation.
Reviewed 2026-09-29.
2001 · Anxiolytic use of the known Bromantane molecule — RU2175229C2Maze/exploration result: Reduced fear-like response in the high-fear strain and increased activity in the more exploratory strain
Anxiolytic use of the known Bromantane molecule — RU2175229C2
S. B. Seredenin, M. A. Yarkova, B. A. Badyshtov, B. M. Pyatin, N. I. Avdyunina, I. S. Morozov, T. A. Voronina, G. G. Neznamov · Russian patent RU2175229C2
Identifies Ladasten as the known Bromantane molecule and cites earlier psychostimulant certificate 860446 and immunostimulant patent 1826906.
Results and tables
Reported patent results
Narrative findings; numerical extraction incomplete
The patent reports less fear-related behavior with greater exploration, alongside behavioral activation.
Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Maze/exploration result | Reduced fear-like response in the high-fear strain and increased activity in the more exploratory strain | No transcribed group means or human anxiety outcome |
| Diazepam comparison | The disclosure describes a different activation/sedation profile | This is a laboratory behavioral distinction, not a clinical noninferiority or safety finding |
Strain-specific animal behavior does not establish broad human anxiety efficacy or absence of stimulant adverse effects. Human clinical records remain separate.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Bromantane/Ladasten plus-maze and exploration comparisons in mouse strains with different baseline fear/exploration patterns.
- Source reviewed
- Original patent text checked, including identity and references to the earlier certificates.
Study limitations
- A new-use patent is not evidence of clinical effectiveness or regulatory status.
- The earlier certificates are cited here; the original documents that would establish priority have yet to be located.
Reviewed 2026-11-06.
2000 · The neuro- and psychophysiological effects of bromantanePrincipal operator performance: No improvement detected
The neuro- and psychophysiological effects of bromantane
O. A. Viatleva, V. G. Barchukov, I. S. Morozov, Iu. A. Salenko, E. N. Zhirnov · Voen Med Zh. 321(8):61–65, 96
The placebo comparison reported EEG and tremor changes, but no change in subjective state or principal operator-performance measures in rested participants.
Results and tables
Reported findings and study design
Ten healthy rested volunteers, single oral Bromantane administration versus placebo; EEG, tremor and operator tests.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Principal operator performance | No improvement detected | |
| Subjective state | No change detected | |
| EEG and tremor | Changes reported | No numerical EEG/tremor effect size or dose in the indexed abstract |
This experiment tested rested participants. Fatigued-operator benefit was a hypothesis, not an observed result.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 10 healthy volunteers
- Source reviewed
- PubMed record and English abstract checked; full paper not reviewed.
Study limitations
- Very small sample and single administration.
- Randomization and allocation details were not established from the abstract.
- The proposed relevance to fatigued operators was not demonstrated by this rested-volunteer comparison.
Reviewed 2026-09-27.
1999 · The mechanisms of the neurotropic action of bromantanRat neuroleptic antagonism: At 5 mg/kg
The mechanisms of the neurotropic action of bromantan
I. S. Morozov, G. S. Pukhova, N. A. Avdulov, S. A. Sergeeva, A. A. Spasov, I. N. Iezhitsa · Eksp Klin Farmakol. 62(1):11–14
Experimental work examined dopamine, serotonin, and noradrenergic responses. These are mechanistic observations, not evidence of human cognitive or sleep benefits.
Results and tables
Reported findings and study design
Animal neurochemical and in-vitro synaptosome experiments.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Rat neuroleptic antagonism | At 5 mg/kg | |
| Dopamine/serotonin uptake block | At 50 microM | |
| Norepinephrine uptake block | Above 500 microM | |
| Mouse serotonergic behavioral effects | 1–20 mg/kg | |
| Cat neuromuscular transmission | No effect at 1–50 mg/kg IV | |
| Central cholinergic effects | Inhibition described at 30–600 mg/kg |
Different species, routes and assay concentrations are not combined into a human potency estimate.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Animal experiments and synaptosomal assays
- Source reviewed
- PubMed record and English abstract checked.
Study limitations
- Species, assays, and exposures differ from everyday human use.
- A neurotransmitter-related signal does not establish a clinical mechanism or long-term safety.
Reviewed 2026-09-27.
Explore related historical combinations ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗